Now, a study published in Cell Communication and Signaling describes new molecular mechanisms to understand insulin resistance in skeletal muscle and to outline future drug targets for DM2.
The study is led by Manuel Vázquez-Carrera, from the UB’s Faculty of Pharmacy and Food Sciences, the Institute of Biomedicine of the UB (IBUB) and the Sant Joan de Déu Research Institute (IRSJD) and the Networking Biomedical Research Center’s Diabetes and Associated Metabolic Diseases area (CIBERDEM).
Other researchers include Ricardo Rodríguez-Calvo (CIBERDEM and Universitat Rovira i Virgili), Antoni Camins (UBNeuro and CIBERNED) and Walter Wahli, from the University of Lausanne (Switzerland).